Biogen will present 23 company-sponsored platform and poster presentations at the International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress, taking place in Toronto, Canada, 20–25 June. The data to be presented underscore the company’s ongoing commitment to hemophilia through continued research with its available therapies and early-stage programs.
Data presentations include a late-breaking platform presentation from the Kids B-LONG study detailing the safety and efficacy of Alprolix [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in children with hemophilia B. This is the first time the full results from the Kids B-LONG study will be publicly presented. In addition, an interim ASPIRE study analysis is focused on the long-term safety and efficacy of Eloctate [Antihemophilic Factor (Recombinant), Fc Fusion Protein] for the prevention and treatment of bleeding in previously treated adults and adolescents with hemophilia A. ASPIRE is a multi-year extension study for people who completed the pivotal, Phase III A-LONG or Kids A-LONG studies.
“The breadth of our research presentations at ISTH reflects our commitment to advancing science and improving care for people with hemophilia,” said Wing-Yen Wong, vice president, Global Medical, Hematology and Immunology at Biogen. “We believe that the comprehensive, growing body of Eloctate and Alprolix clinical data will continue to help clinicians understand the benefits of these therapies as they work with their patients to make treatment decisions.”
Eloctate and Alprolix are the first approved hemophilia A and B therapies to provide bleeding protection with the potential to extend the interval between prophylactic infusions. They were developed using a process called Fc fusion, which was designed to prolong a therapy’s circulation in the body using a naturally occurring pathway. While Fc fusion has been used for more than 15 years, Biogen is the only company to apply it to the treatment of hemophilia.
